%0 Journal Article
%A Aglago, Elom K
%A Schalkwijk, Casper G
%A Freisling, Heinz
%A Fedirko, Veronika
%A Hughes, David J
%A Jiao, Li
%A Dahm, Christina C
%A Olsen, Anja
%A Tjønneland, Anne
%A Katzke, Verena
%A Johnson, Theron
%A Schulze, Matthias B
%A Aleksandrova, Krasimira
%A Masala, Giovanna
%A Sieri, Sabina
%A Simeon, Vittorio
%A Tumino, Rosario
%A Macciotta, Alessandra
%A Bueno-de-Mesquita, Bas
%A Skeie, Guri
%A Gram, Inger Torhild
%A Sandanger, Torkjel
%A Jakszyn, Paula
%A Sánchez, Maria-Jose
%A Amiano, Pilar
%A Colorado-Yohar, Sandra M
%A Gurrea, Aurelio Barricarte
%A Perez-Cornago, Aurora
%A Mayén, Ana-Lucia
%A Weiderpass, Elisabete
%A Gunter, Marc J
%A Heath, Alicia K
%A Jenab, Mazda
%T Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.
%J Carcinogenesis
%V 42
%N 5
%@ 1460-2180
%C Oxford
%I Oxford Univ. Press
%M DKFZ-2021-00733
%P 705-713
%D 2021
%Z 2021 May 28;42(5):705-713
%X Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino-acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case-control study nested within a large European cohort. Plasma concentrations of three protein-bound AGEs: N ε-(carboxy-methyl)lysine (CML), N ε-(carboxy-ethyl)lysine (CEL) and N δ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were measured by ultra-performance liquid chromatography tandem mass-spectrometry in baseline samples collected from 1,378 incident primary colorectal cancer cases and 1,378 matched controls. Multivariable-adjusted odds ratios (ORs) and 95
%K Advanced glycation end-product (Other)
%K colorectal cancer (Other)
%K glycotoxin (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33780524
%R 10.1093/carcin/bgab026
%U https://inrepo02.dkfz.de/record/168193